Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroblastoma × SF 1126 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Squamous Cell Carcinoma of Head and Neck 1 Neuroblastoma 1 Neoplasm Metastasis 1 Hereditary Sensory and Autonomic Neuropathies 1

Interventions

Cyclophosphamide 47 Etoposide 27 Irinotecan 25 Temozolomide 24 Melphalan 24 3-Iodobenzylguanidine 22 Topotecan 20 Filgrastim 20 Isotretinoin 19 Carboplatin 18 Granulocyte Colony-Stimulating Factor 16 sargramostim 15 fludarabine 15 Granulocyte-Macrophage Colony-Stimulating Factor 15 humanized 3F8 anti-GD2 monoclonal antibody 14 dinutuximab 13 Peripheral Blood Stem Cell Transplantation 13 Doxorubicin 13 Cisplatin 13 Radiotherapy 12 Interleukin-2 12 Busulfan 12 naxitamab 11 Vincristine 11 fludarabine phosphate 10 aldesleukin 9 Thiotepa 9 Eflornithine 8 Vorinostat 7 Stem Cell Transplantation 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02337309 2018-08-20

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Terminated

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡